Literature DB >> 3266207

Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR,DP monoclonal antibody CR11-462.

F Perosa1, S Ferrone.   

Abstract

Two out of 625 hybridomas constructed with splenocytes from a Balb/c mouse immunized with the murine anti-HLA-DR, DP monoclonal antibody CR11-462 secrete antiidiotypic antibodies. Binding assays with a panel of 12 anti-HLA class I, 14 anti-HLA class II, and 9 anti-human melanoma-associated antigen MoAbs showed that the idiotopes recognized by MoAb F3-C25 and F3-B6 are not expressed by any of the tested antibodies, even those which inhibit the binding of MoAb CR11-462 to cultured B lymphoid cells. Crossblocking experiments showed that the two idiotopes are distinct and spatially distant. Both idiotopes require the association of heavy and light chain of MoAb CR11-462 for their expression. The idiotope recognized by MoAb F3-B6 is an alpha idiotope, since it is located outside the antigen combining site of MoAb CR11-462. The idiotope recognized by MoAb F3-C25 is a gamma idiotope, since it is antigen inhibitable but does not possess an internal image of the antigen. Interestingly the MoAb F3-C25 displays a differential inhibitory effect on the binding of MoAb CR11-462 to lymphoid cells that express different HLA phenotypes or share the HLA-DRw6 allospecificity. These results suggest that antiidiotypic antibodies may sharpen our ability to dissect the heterogeneity of HLA class II antigens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3266207     DOI: 10.1016/0198-8859(88)90061-4

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

1.  Diversity of anti-HLA-DR antibodies elicited by distinct anti-idiotypic monoclonal antibodies recognizing idiotopes co-expressed by the immunizing monoclonal antibody.

Authors:  S M Mariani; E A Armandola; S Ferrone
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

2.  Anti-idiotypic monoclonal antibodies reacting with idiotope on isolated-denatured chains of an anti-CD4 monoclonal antibody.

Authors:  F Perosa; S Ferrone; F Dammacco
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

3.  Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.

Authors:  Chien-Chung Chang; Michael Campoli; Nicholas P Restifo; Xinhui Wang; Soldano Ferrone
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

4.  Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities.

Authors:  F Perosa; S Ferrone
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

5.  The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.

Authors:  Ling Yu; Elvira Favoino; Yangyang Wang; Yang Ma; Xiaojuan Deng; Xinhui Wang
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

6.  Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

Authors:  A Mittelman; Z J Chen; T Kageshita; H Yang; M Yamada; P Baskind; N Goldberg; C Puccio; T Ahmed; Z Arlin
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

7.  CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

Authors:  Xinhui Wang; Takuya Osada; Yangyang Wang; Ling Yu; Koichi Sakakura; Akihiro Katayama; James B McCarthy; Adam Brufsky; Mamatha Chivukula; Thaer Khoury; David S Hsu; William T Barry; H Kim Lyerly; Timothy M Clay; Soldano Ferrone
Journal:  J Natl Cancer Inst       Date:  2010-09-17       Impact factor: 13.506

8.  Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.

Authors:  Chien-Chung Chang; Giuseppe Pirozzi; Shao-Hsuan Wen; I-Hsin Chung; Bau-Lin Chiu; Simona Errico; Monica Luongo; Maria Luisa Lombardi; Soldano Ferrone
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

9.  Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis.

Authors:  Elvira Favoino; Liboria Digiglio; Giovanna Cuomo; Isabella E Favia; Vito Racanelli; Gabriele Valentini; Federico Perosa
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.